Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 cemiplimab for cutaneous squamous cell carcinoma with large-nerve perineural spread
ACTRN12625000197437Phase 2Not yet recruiting
- Sponsor
- Metro South Health
- Start
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Metro South Health. Primary endpoint: Landmark progression-free survival at Week 12. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on ACTRN12625000197437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000197437.